ImmunityBio Inc. (IBRX) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    ImmunityBio Inc.

    NASDAQ: IBRX · Real-Time Price · USD
    2.54
    0.04 (1.60%)
    At close: Oct 03, 2025, 3:59 PM

    ImmunityBio Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 -413.64M -583.2M -417.32M -349.85M
    Depreciation & Amortization
    		 17.55M 18.51M 18.26M 14.24M
    Stock-Based Compensation
    		 34.43M 49.16M 40.18M 57.18M
    Other Working Capital
    		 -5.62M 10.45M -16M -15.39M
    Other Non-Cash Items
    		 -10.15M 144.79M 29.38M 23.13M
    Deferred Income Tax
    		 n/a n/a -4K -8K
    Change in Working Capital
    		 -19.42M 3.98M -8M -19.11M
    Operating Cash Flow
    		 -391.24M -366.76M -337.51M -274.42M
    Capital Expenditures
    		 -6.89M -30.58M -99.39M -33.56M
    Cash Acquisitions
    		 -1M n/a -1M 20.5M
    Purchase of Investments
    		 -140.22M -10.36M -34.31M -141.75M
    Sales Maturities Of Investments
    		 136.61M 10.47M 162M 69.93M
    Other Investing Acitivies
    		 -747K n/a 105.46M -51.32M
    Investing Cash Flow
    		 -12.25M -30.47M 27.3M -84.89M
    Debt Repayment
    		 -64K 258.62M 174.07M 338.5M
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 170.34M 189.62M -881K 2.41M
    Financial Cash Flow
    		 281.63M 558.34M 233.61M 505.44M
    Net Cash Flow
    		 -121.88M 160.82M -76.31M 146.19M
    Free Cash Flow
    		 -398.12M -397.34M -436.9M -307.98M

    Add to Watchlist